Results 181 to 190 of about 25,109 (253)

The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding. [PDF]

Nucleic Acids Res
Wang S, Santacana-Font G, Kedra D, Gilfillan S, Tena-Chaves D, Bergholtz H, Engebraaten O, Lingjaerde OC, Gutiérrez-Fernández J, Norum JH, Sørlie T, López-Aviles S, Hurtado A.   +12 more
europepmc   +1 more source

Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis

Hiroyuki Fujii, Hirokazu Shoji, Hidekazu Hirano, Toshiharu Hirose, Natsuko Okita, Atsuo Takashima, Ken Kato   +6 more
openalex   +1 more source

Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation. [PDF]

Sci Adv
Vacca S, Gragera M, Buschiazzo A, Herreros D, Krieger JM, Bonn-Garcia S, Melero R, Sorzano CO, Carazo JM, Medalia O, Plückthun A.   +10 more
europepmc   +1 more source

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

, 2016
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie‐Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin, Thierry Chardès   +8 more
openalex   +2 more sources

Cancer-associated Fibroblasts Confer Osimertinib Resistance in Non-small Cell Lung Cancer Cells via NRG1-mediated HER3/AKT Signaling. [PDF]

J Cancer
Zheng S, Cao L, Zhang J, Zhang Q, Ren Y, Wang M, Qian Y, Li B, Wu X, Meng Z, Xu K.   +10 more
europepmc   +1 more source

Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer. [PDF]

Oncol Ther
Xie B, Chen C, Cai H, Wang L, Chen M, Liu J, Wu F, Huang W.   +7 more
europepmc   +1 more source

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. [PDF]

Biomolecules
Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, Um W.   +6 more
europepmc   +1 more source

A study protocol of a single-arm, prospective, open-label, non-controlled, phase II study of neoadjuvant BL-B01D1 combined with aumolertinib in resectable stage II-IIIB non-small cell lung cancer patients with <i>EGFR</i> mutation. [PDF]

Transl Lung Cancer Res
Chen Y, Mei J, Gao G, Zhang B, Li Y, Peng Z, Li C, Gan F, Pu Q, Liu C, Yang W, Liu L, Wang Y.   +12 more
europepmc   +1 more source

HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver

, 2015
Frida Lédel, Kristina Stenstedt, Marja Hallström, Peter Ragnhammar, David Edler   +4 more
openalex   +1 more source

Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. [PDF]

NPJ Breast Cancer
Valle I, Grinda T, Antonuzzo L, Pistilli B.   +3 more
europepmc   +1 more source